1. Home
  2. PRLD vs INVE Comparison

PRLD vs INVE Comparison

Compare PRLD & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • INVE
  • Stock Information
  • Founded
  • PRLD 2016
  • INVE 1990
  • Country
  • PRLD United States
  • INVE United States
  • Employees
  • PRLD N/A
  • INVE N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • INVE Computer peripheral equipment
  • Sector
  • PRLD Health Care
  • INVE Technology
  • Exchange
  • PRLD Nasdaq
  • INVE Nasdaq
  • Market Cap
  • PRLD 73.7M
  • INVE 82.2M
  • IPO Year
  • PRLD 2020
  • INVE 1997
  • Fundamental
  • Price
  • PRLD $0.68
  • INVE $2.99
  • Analyst Decision
  • PRLD Strong Buy
  • INVE Strong Buy
  • Analyst Count
  • PRLD 2
  • INVE 3
  • Target Price
  • PRLD $4.50
  • INVE $6.83
  • AVG Volume (30 Days)
  • PRLD 272.4K
  • INVE 68.0K
  • Earning Date
  • PRLD 05-06-2025
  • INVE 05-07-2025
  • Dividend Yield
  • PRLD N/A
  • INVE N/A
  • EPS Growth
  • PRLD N/A
  • INVE N/A
  • EPS
  • PRLD N/A
  • INVE 3.14
  • Revenue
  • PRLD $7,000,000.00
  • INVE $26,628,000.00
  • Revenue This Year
  • PRLD N/A
  • INVE N/A
  • Revenue Next Year
  • PRLD N/A
  • INVE $10.34
  • P/E Ratio
  • PRLD N/A
  • INVE $0.95
  • Revenue Growth
  • PRLD N/A
  • INVE N/A
  • 52 Week Low
  • PRLD $0.63
  • INVE $2.90
  • 52 Week High
  • PRLD $6.80
  • INVE $5.64
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 41.40
  • INVE 35.55
  • Support Level
  • PRLD $0.71
  • INVE $3.20
  • Resistance Level
  • PRLD $0.76
  • INVE $3.39
  • Average True Range (ATR)
  • PRLD 0.07
  • INVE 0.19
  • MACD
  • PRLD 0.01
  • INVE -0.02
  • Stochastic Oscillator
  • PRLD 18.75
  • INVE 14.75

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About INVE Identiv Inc.

Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.

Share on Social Networks: